WO2018220886A1 - リポ多糖を用いた脳機能改善剤、食品及び医薬品 - Google Patents

リポ多糖を用いた脳機能改善剤、食品及び医薬品 Download PDF

Info

Publication number
WO2018220886A1
WO2018220886A1 PCT/JP2017/043429 JP2017043429W WO2018220886A1 WO 2018220886 A1 WO2018220886 A1 WO 2018220886A1 JP 2017043429 W JP2017043429 W JP 2017043429W WO 2018220886 A1 WO2018220886 A1 WO 2018220886A1
Authority
WO
WIPO (PCT)
Prior art keywords
food
brain
pantoea
lps
improving agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/043429
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
源一郎 杣
裕之 稲川
千恵 河内
優多郎 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Control Of Innate Immunity Technology Research Association
Kagawa University NUC
Original Assignee
Control Of Innate Immunity Technology Research Association
Kagawa University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Of Innate Immunity Technology Research Association, Kagawa University NUC filed Critical Control Of Innate Immunity Technology Research Association
Priority to CN201780091325.7A priority Critical patent/CN110691599B/zh
Priority to KR1020197038343A priority patent/KR20200011490A/ko
Priority to BR112019024953-2A priority patent/BR112019024953A2/pt
Priority to IL270936A priority patent/IL270936B2/en
Priority to EP17911728.8A priority patent/EP3643314B1/en
Priority to US16/617,540 priority patent/US11278564B2/en
Priority to KR1020227004771A priority patent/KR20220025912A/ko
Publication of WO2018220886A1 publication Critical patent/WO2018220886A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a brain function improving agent, a food and a medicine containing lipopolysaccharide.
  • Alzheimer's disease In recent years, the total population has decreased in Japan, while the elderly population over 65 years of age has been increasing year by year. According to the Ministry of Health, Labor and Welfare, the elderly population (2015) exceeds 33 million and the aging rate has reached 26.7%.
  • dementia one of the elderly diseases, the number of patients in Japan currently exceeds 4.6 million, and in 2025, it is expected to be 7 million, one in five elderly people.
  • About 60% of patients with dementia have Alzheimer's disease, about 20% have vascular dementia, and the rest include various dementia diseases such as Lewy body dementia.
  • Clinical symptoms of Alzheimer's disease include cognitive dysfunction such as memory impairment and language impairment, psychiatric symptoms, behavioral disorders and the like.
  • amyloid plaques As a pathological feature of Alzheimer's disease, senile plaques called amyloid plaques and abnormal structures such as neurofibrillary tangles may be deposited in a wide range of cerebral cortex and hippocampus.
  • the main constituent of amyloid plaques is amyloid ⁇ protein (hereinafter also simply referred to as “A ⁇ ”), and in particular, A ⁇ peptide consisting of 42 residues (hereinafter also simply referred to as “A ⁇ 1-42”) has high aggregation properties, It is known to play a central role in amyloid deposition. The latter is an overphosphorylated tau protein.
  • a ⁇ amyloid ⁇ protein
  • a ⁇ 1-42 A ⁇ peptide consisting of 42 residues
  • Non-patent Document 1 A ⁇ also appears in the brain of a healthy person with aging, but it is believed that A ⁇ accumulation is promoted by gene mutation of an enzyme involved in A ⁇ production or a decrease in activity of the A ⁇ degradation system.
  • therapeutic agents for Alzheimer's disease therapeutic agents targeting neurotransmitters and their receptors (acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists) have been developed, but accumulation of A ⁇ It is not a therapeutic agent for treating pathological changes such as aggregation of tau protein and tau protein, and is therefore not a fundamental therapeutic agent capable of preventing the progression of Alzheimer's disease.
  • microglia which are macrophages in brain tissue, have been shown to play an important role in maintaining homeostasis in the brain, such as repairing damaged tissues and removing phagocytosis of waste products in the brain.
  • Microglia expresses A ⁇ receptor, and it takes up and degrades A ⁇ by phagocytic reaction. Therefore, activation of A ⁇ phagocytic activation of microglia prevents Alzheimer's disease caused by excessive accumulation of A ⁇ . Can be expected.
  • Non-patent Document 2 oleic acid amide
  • Patent Document 1 peptides
  • lipopolysaccharide is one of the outer membrane components of the cell wall of Gram-negative bacteria.
  • endotoxin was given to the toxic substance derived from Vibrio cholerae in 1892, and it was reported in 1954 that the main body of endotoxin is lipopolysaccharide (Non-patent Document 3).
  • Non-patent Document 4 it has been reported that intracranial injection of lipopolysaccharide into Alzheimer's disease model mice induces microglia activation and suppresses the deposition of A ⁇ in the brain.
  • Non-Patent Document 5 MPL (Monophosphoryl lipid A), a derivative of lipid A, a component of lipopolysaccharide and approved as an adjuvant (immunostimulant), suppresses A ⁇ brain deposition and improves learning function It has been reported to show an action (Non-Patent Document 5).
  • oral or percutaneous ingestion of lipopolysaccharide has no apparent toxicity and has been reported to show an improving effect on diseases such as hyperlipidemia and allergy (Non-patent Document 6).
  • lipopolysaccharide (hereinafter also referred to as “Pantoea LPS”) derived from the wheat symbiotic bacterium Pantoea agglomerans, and is used in cosmetics, foods and functional foods.
  • Pantoea LPS lipopolysaccharide
  • Patent Document 2 Fukasaka et al. Reported in animal experiments that Pantoea LPS administered sublingually acts as an adjuvant and enhances mucosal immune activity.
  • Non-patent Document 7 Furthermore, Kobayashi et al.
  • Non-patent Document 8 Lipopolysaccharide administered orally is hardly absorbed from the digestive tract.
  • starch for example, humans are digested because they have enzymes (amylase, maltase) that digest starch (alpha polysaccharide linked to ⁇ 1-4 of glucose) (Wikipedia, starch), but LPS These polysaccharides are composed of 3-5 types of 6- and 5-carbon sugars (Wikipedia, Lipopolysaccharide), and since humans do not have digestive enzymes that can degrade LPS polysaccharide structures, they are not digested.
  • the intracerebral translocation since there is a brain-blood barrier with regard to intracerebral translocation, even if lipopolysaccharide is absorbed into the blood by oral administration, the intracerebral translocation will further decrease the efficiency. It is thought that it does not reach the brain. So far, the A ⁇ brain deposition inhibitory effect or learning function improving effect by oral administration of lipopolysaccharide has not been reported so far and is not described in any literature.
  • the present invention has been made in view of the background as described above, and has the effect of suppressing A ⁇ brain deposition or learning function by lipopolysaccharide that is relatively easily available by the fermentation culture method (Patent Document 2). It is an object of the present invention to provide a brain function improving agent, food and medicine having an improvement effect.
  • Pantoea LPS was orally administered to Alzheimer's disease model mice and the effects were examined. As a result, it was found that oral administration of Pantoea LPS significantly reduced the amount of A ⁇ peptide accumulated in the brain and improved the learning function, thereby completing the present invention.
  • the brain function improving agent of the present invention is for Alzheimer's disease, characterized by containing Pantoea LPS as an active ingredient.
  • the present invention has the following configuration.
  • a brain function improving agent, food, or pharmaceutical comprising lipopolysaccharide comprising Pantoea LPS as an active ingredient.
  • the brain function-improving agent, food or medicine according to claim 1, wherein the brain function to be improved is a cognitive function reduced due to aging or a brain disease accompanying aging.
  • the brain function improving agent, food or pharmaceutical product according to claim 1, comprising an effective amount of Pantoea bacteria LPS.
  • the brain function improving agent, food or pharmaceutical product according to claim 1 for preventing Alzheimer's disease.
  • Pantoea LPS can provide a composition such as a drug or food having an effect of preventing Alzheimer's disease, particularly an effect of suppressing A ⁇ brain deposition and an effect of improving learning function. Since Pantoea LPS has been confirmed to be safe for oral or transdermal administration in forms such as food, cosmetics, and feed, it can be expected to have a preventive effect with a low risk of side effects.
  • the result of the training test in the water maze test is shown. It is a graph which shows that the time required to reach the platform was shortened in all groups by continuous training for 5 days. There is no difference between groups.
  • the typical swimming locus in the probe test in the water maze test is shown.
  • the dotted circle indicates the position where the platform was installed.
  • the result of the time when the mouse stayed in the quadrant area where the platform was installed is shown.
  • the PC group that ingested the high-fat diet showed a decrease in residence time, whereas Pantoea LPS ingestion prolonged the residence time.
  • the brain function improving agent and food composition of the present invention contain Pantoea bacteria LPS.
  • Pantoea bacterium LPS is a gram-negative bacterium symbiotic pantoea agglomerans (Pantoea agglomerans) cultivated in wheat flour according to the procedure described in Patent Document 2 unless otherwise specified. Lipopolysaccharide from which lipopolysaccharide is extracted with hot water to remove solids.
  • the brain function improving agent and food of the present invention can improve cerebral dysfunction, particularly cognitive dysfunction, caused by aging or brain diseases associated with aging.
  • cerebral dysfunction particularly cognitive dysfunction
  • a brain disease associated with cognitive dysfunction for example, Alzheimer's disease can be specified.
  • Pantoea bacterium LPS of the present invention can be applied to humans, non-human mammals (domestic animals such as pigs, cows, sheep, horses, dogs and cats), birds (poultry such as chickens, turkeys and ducks).
  • the administration route and dosage form of the pharmaceutical composition of the present invention can be appropriately designed according to the purpose, symptom, subject's age, weight and the like.
  • administration routes include oral administration, transdermal administration, buccal administration, subcutaneous injection, intradermal injection, intraperitoneal injection, and intramuscular administration. Oral administration, transdermal administration, and buccal administration are preferable.
  • dosage forms include powders, granules, liquids, capsules, fine granules, pills, syrups, and emulsions. This pharmaceutical composition can be administered orally and is effective.
  • Pantoea LPS various pharmaceutically acceptable additives in addition to Pantoea LPS, such as stabilizers, fillers, emulsifiers, bulking agents, excipients, binders, humectants, disintegrants, interfaces.
  • An active agent, a suspending agent, a coating agent, a coloring agent, a fragrance, a flavoring agent, a sweetening agent, a preservative, and an antioxidant can be contained.
  • the food composition of the present invention can be used according to conventional methods in food compositions, such as using Pantoea LPS as it is or mixing with other foods or food ingredients. Further, the form thereof is not particularly limited, and may be a commonly used food state such as solid (powder, granule, etc.), paste, liquid or suspension.
  • the food composition of the present invention may be a nutritional functional food, a food for specified health use, a functional indication food, a health food, a nutritional supplement, a drink, a soft drink, an alcoholic beverage, a supplement, a feed, a feed additive, or the like. it can.
  • the brain function improving agent or food composition of the present invention is preferably formulated so as to contain Pantoea LPS in the range of 0.1 to 1 mg / kg body weight per day for an adult when taken orally.
  • Such a dose can be appropriately adjusted according to various factors such as the age, weight, health status, administration method, and combination with other agents (or food ingredients) of the subject. When ingested for the purpose of prevention over a long period of time, the amount may be smaller than the above range.
  • Example 1 Test Method for Oral Administration of Pantoea LPS to Alzheimer's Disease Model Mice
  • Pantoea LPS was prepared and purified according to a lipopolysaccharide fermentation culture method (Patent Document 2) developed by Tsuji et al. (Lipopolysaccharide, Pantoea agglomerans ⁇ LPS>, innate immunity applied engineering company) was used.
  • Patent Document 2 Lipopolysaccharide, Pantoea agglomerans ⁇ LPS>, innate immunity applied engineering company
  • a feed containing 35% fat (research diet) was given, and water containing 0.3 or 1 mg / kg body weight / day of Pantoea LPS was given orally by free drinking.
  • the control group was given a feed containing 35% fat or a feed containing 4% fat (research diet), and water was given in the same manner.
  • Mice were raised in an animal facility controlled for temperature and humidity under free environmental conditions under free feeding, free drinking, 12 hours of light irradiation / 12 hours of darkness. After 17 weeks of breeding, the following water maze test was conducted for 1 week to evaluate the learning function. The day after the water maze test was completed, blood was collected from the heart. Brain, liver, and epididymal white adipocytes were removed. This animal experiment has been approved by the Kagawa University Animal Experiment Committee.
  • Non-patent Document 9 male SAMP8 mice were used as Alzheimer's disease model mice. Since this mouse exhibits Alzheimer's disease-like symptoms such as an increase in brain A ⁇ deposition amount and a decrease in learning function with aging, it is used as an aging promoting model mouse. In addition, high-fat diet intake has been reported to accelerate the development of Alzheimer's disease by inducing type 2 diabetes-like symptoms such as increased fasting blood glucose levels and increased HbA1c levels. (Non-patent document 10).
  • mice were divided into the following 4 groups.
  • NC group Feed containing 4% fat (low fat feed) and water were given by free consumption.
  • PC group A feed containing 35% fat (high fat feed) and water were given by free consumption.
  • Pantoea bacteria LPS 0.3 mg / kg body weight / day group High-fat diet and water containing Pantoea bacteria LPS (0.3 mg / kg body weight / day) were given by free consumption.
  • Pantoea bacteria LPS 1 mg / kg body weight / day group High-fat diet and water containing Pantoea bacteria LPS (1 mg / kg body weight / day) were given by free consumption.
  • a mouse was placed in a pool from an arbitrary position, allowed to swim for 60 seconds, and searched for a platform placed 1 cm below the surface of the water. The time required to reach the platform was recorded, and if it could not be reached in 60 seconds, it was recorded as 60 seconds. Mice that did not reach the platform in time were guided to the platform by the experimenter. After reaching the platform, the mouse was left for 20 seconds and the mouse was removed from the pool. The probe test was performed on the 6th day. For the probe test, the platform was removed from the pool, the mouse was allowed to swim for 60 seconds, and the time spent in each quadrant of the pool was measured. The probe test was performed once for each mouse.
  • the blood glucose level was measured using a blood glucose level measuring device (Roche diagnostics), and HbA1c was measured using an enzyme method measurement kit (Sekisui Medical). Triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol in plasma were measured using an enzyme assay kit (Wako Pure Chemical Industries). Oxidized LDL in plasma was measured using an ELISA kit (Kamiya Biomedical Company). The amount of A ⁇ peptide accumulated in the brain was measured using an ELISA kit (Wako Pure Chemical Industries, Ltd.). According to the protocol of the instruction manual, A ⁇ fraction was prepared from the excised mouse cerebral sample, and A ⁇ 1-42 and A ⁇ peptide (A ⁇ 1-40) consisting of 40 residues were respectively quantified. The results were expressed as an average value and a standard error (SEM) of the average value. In addition, a one-way analysis of variance was performed according to Tukey-Kramer's multiple comparison. Different signs indicate significant difference at P ⁇ 0.05.
  • Pantoea LPS As a result of analyzing blood lipids, a clear decrease in total cholesterol and LDL cholesterol was observed in the Pantoea LPS administration group. HDL cholesterol was clearly elevated in the Pantoea LPS 1 mg / kg body weight / day group compared to the PC group. Further, the plasma oxidized LDL was lower in Pantoea LPS 1.0 mg / kg body weight / day than in Pantoea LPS 0.3 mg / kg body weight / day compared to the PC group (Table 1). This indicates that oral administration of Pantoea LPS improves sugar metabolism and lipid metabolism in SAMP8 mice fed with high fat diet. So far, Nakada et al.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/JP2017/043429 2017-05-28 2017-12-04 リポ多糖を用いた脳機能改善剤、食品及び医薬品 Ceased WO2018220886A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201780091325.7A CN110691599B (zh) 2017-05-28 2017-12-04 使用脂多糖的脑功能改善剂、食品和药品
KR1020197038343A KR20200011490A (ko) 2017-05-28 2017-12-04 리포 다당을 사용한 뇌기능 개선제, 식품 및 의약품
BR112019024953-2A BR112019024953A2 (pt) 2017-05-28 2017-12-04 Agente, alimento ou medicamento para melhorar a função cerebral
IL270936A IL270936B2 (en) 2017-05-28 2017-12-04 A factor, food and drug that improve brain activity through lipopolysaccharide
EP17911728.8A EP3643314B1 (en) 2017-05-28 2017-12-04 Brain function-improving agent, food, and medicine using lipopolysaccharide
US16/617,540 US11278564B2 (en) 2017-05-28 2017-12-04 Brain function-improving agent, food, and medicine using lipopolysaccharide
KR1020227004771A KR20220025912A (ko) 2017-05-28 2017-12-04 리포 다당을 사용한 뇌기능 개선제, 식품 및 의약품

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017105133A JP6998133B2 (ja) 2017-05-28 2017-05-28 リポ多糖を用いた脳機能改善剤、食品及び医薬品
JP2017-105133 2017-05-28

Publications (1)

Publication Number Publication Date
WO2018220886A1 true WO2018220886A1 (ja) 2018-12-06

Family

ID=64455394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/043429 Ceased WO2018220886A1 (ja) 2017-05-28 2017-12-04 リポ多糖を用いた脳機能改善剤、食品及び医薬品

Country Status (8)

Country Link
US (1) US11278564B2 (enExample)
EP (1) EP3643314B1 (enExample)
JP (2) JP6998133B2 (enExample)
KR (2) KR20200011490A (enExample)
CN (1) CN110691599B (enExample)
BR (1) BR112019024953A2 (enExample)
IL (1) IL270936B2 (enExample)
WO (1) WO2018220886A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243934A4 (en) * 2020-11-13 2024-07-31 National Health Research Institutes Method for treating amyloidogenic disease

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6998133B2 (ja) * 2017-05-28 2022-01-18 自然免疫制御技術研究組合 リポ多糖を用いた脳機能改善剤、食品及び医薬品
JP7679216B2 (ja) * 2021-04-07 2025-05-19 有限会社バイオメディカルリサーチグループ リポ多糖製造方法、リポ多糖、及びその配合物
AU2022464309A1 (en) 2022-06-22 2025-01-23 Biomedical Research Group Inc. Prophylactic drug and therapeutic drug for diabetes-associated dementia
KR102555274B1 (ko) 2022-12-03 2023-07-13 김환배 분리형 측면 미세먼지 집진휀스로 세척이 용이한 고기구이기

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011193877A (ja) 2003-09-26 2011-10-06 Genichiro Soma 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物
JP2016193865A (ja) 2015-03-31 2016-11-17 キリン株式会社 ミクログリア貪食活性亢進のための組成物及びミクログリア貪食活性亢進作用の予測方法
JP2017105133A (ja) 2015-12-11 2017-06-15 株式会社リコー 制御装置、液体を吐出する装置、印刷物の生産方法及びプログラム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170055487A (ko) * 2014-10-02 2017-05-19 닛토덴코 가부시키가이샤 경피 투여용 백신 의약 조성물
JP6998133B2 (ja) 2017-05-28 2022-01-18 自然免疫制御技術研究組合 リポ多糖を用いた脳機能改善剤、食品及び医薬品

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011193877A (ja) 2003-09-26 2011-10-06 Genichiro Soma 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物
JP2016193865A (ja) 2015-03-31 2016-11-17 キリン株式会社 ミクログリア貪食活性亢進のための組成物及びミクログリア貪食活性亢進作用の予測方法
JP2017105133A (ja) 2015-12-11 2017-06-15 株式会社リコー 制御装置、液体を吐出する装置、印刷物の生産方法及びプログラム

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
0. WESTPAL ET AL., ANGEWANDTE CHEMIE, vol. 66, 1954, pages 407 - 417
C. KOHCHI ET AL., JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 102, 2006, pages 485 - 496
D. L. HERBER ET AL., JOURNAL OF NEUROIMMUNE PHARMACOLOGY, vol. 2, 2007, pages 222 - 231
HIROYUKI INAGAWA, YUTARO KOBAYASHI, CHIE KOHCHI, RAN ZHANG, YASUHIRO SHIBASAKI, AND GEN-ICHIRO SOMA: "Primed Activation of Macrophages by Oral Administration of Lipopolysaccharide Derived from Pantoea agglomerans", IN VIVO, vol. 30, no. 3, May 2016 (2016-05-01), pages 205 - 211, XP055634562, ISSN: 0258-851X *
IKEDA, SATSUYA ET AL.: "Discussion of phagocytosis function activated of pantoea agglomerans-derived LPS in macrophge cell line RAW 264.7", 20TH ANNUAL MEETING OF THE BIOTHERAPY RESEARCH SOCIETY, PROGRAM/ABSTRACTS; 10/12/2016, 2016, JAPAN, pages 42, XP009518527 *
J. E. MORLEY ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1822, 2012, pages 650 - 656
J. HARDY ET AL., SCIENCE, vol. 297, 2002, pages 353 - 356
J. MEHLA ET AL., JOURNAL OF ALZHEIMER'S DISEASE, vol. 39, 2014, pages 145 - 162
J. P. MICHAUD ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, 1941
K. NAKATA ET AL., NUTRITION RESEARCH AND PRACTICE, vol. 5, 2011, pages 435 - 442
KOBAYASHI, Y. ET AL.: "Effect of Lipopolysaccharide derived from Pantoea agglomerans on the Phagocytic activity of Amyloid beta by primary marine microglial cells", ANTICANCER RESEARCH, vol. 36, no. 7, 2016, pages 3693 - 3698, XP055634553, ISSN: 0250-7005 *
M. FUKASAKA ET AL., PLOS ONE, vol. 10, 2015, pages e0126849
NEUROINFORMATICS, vol. 14, 2016, pages 479 - 481
Y. KOBAYASHI ET AL., ANTICANCER RESEARCH, vol. 36, 2016, pages 3693 - 3698

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243934A4 (en) * 2020-11-13 2024-07-31 National Health Research Institutes Method for treating amyloidogenic disease

Also Published As

Publication number Publication date
BR112019024953A2 (pt) 2020-06-23
EP3643314C0 (en) 2023-08-30
KR20220025912A (ko) 2022-03-03
IL270936A (en) 2020-01-30
KR20200011490A (ko) 2020-02-03
EP3643314A4 (en) 2021-04-07
JP2018199643A (ja) 2018-12-20
EP3643314A1 (en) 2020-04-29
CN110691599A (zh) 2020-01-14
US20200179436A1 (en) 2020-06-11
US11278564B2 (en) 2022-03-22
JP2021169506A (ja) 2021-10-28
CN110691599B (zh) 2023-05-02
JP6998133B2 (ja) 2022-01-18
IL270936B2 (en) 2023-10-01
IL270936B1 (en) 2023-06-01
EP3643314B1 (en) 2023-08-30
JP7809461B2 (ja) 2026-02-02

Similar Documents

Publication Publication Date Title
JP7809461B2 (ja) リポ多糖を用いた脳機能改善剤、食品及び医薬品
JP6012111B2 (ja) 動物用飼料添加物
US20190314425A1 (en) Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease or metabolic disease and use thereof
TW201134470A (en) Anaplerotic therapy for Alzheimer's disease and the aging brain
CN110621311A (zh) 淀粉样蛋白β分解排出促进剂
JPWO2002030418A1 (ja) 脂質代謝改善用組成物
ES2973249T3 (es) Composición que comprende cepa de Agathobaculum sp. como ingrediente efectivo para la prevención, alivio o tratamiento del trastorno del espectro autista
JP5769912B2 (ja) 認知障害を伴う疾患又は状態の予防又は治療用の組成物
US11554162B2 (en) Pharmaceutical or food supplement preparation based on alpha-lactalbumin
KR102037944B1 (ko) 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물
JP7449511B2 (ja) 加齢に伴う認知機能の低下予防又は改善用の組成物
HK40015331B (en) Brain function-improving agent, food, and medicine using lipopolysaccharide
HK40015331A (en) Brain function-improving agent, food, and medicine using lipopolysaccharide
US20240115530A1 (en) Administration of baiba to increase benefit of losing weight of intermittent fasting
JP7181695B2 (ja) 抗認知症剤及び短期記憶障害改善／抑制剤
AU2019211717B2 (en) Anti-I-type allergy agent, degranulation inhibitor for basophils and mast cells, anti-dementia agent, agent for improving/inhibiting short-term memory impairment
EP3195734B1 (fr) Complement alimentaire pour utilisation dans la lutte contre le stress et l'anxiete chez les animaux de compagnie
Dhanalakshmi et al. Protective effect of Picrorrhiza kurroa on ochratoxin A induced oxidative stress in chickens
JP2018008895A (ja) 認知機能低下抑制又は予防剤
JP2016102068A (ja) 鯨筋肉抽出物からなる中長期記憶障害予防改善剤
KR20170139380A (ko) 모노아세틸디아실글리세롤 화합물을 함유하는 집중력 향상 또는 인지기능 장애 질환 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17911728

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019024953

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197038343

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017911728

Country of ref document: EP

Effective date: 20200102

ENP Entry into the national phase

Ref document number: 112019024953

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191127